Tuesday, 23 Apr 2019

You are here

Low Risk of Serious Complications with Meniscectomy

Lancet reports on the safety of over 1 million arthroscopic partial meniscectomies done in the United Kingdom and found a low overall risk in the first 90 days.

They examined Hospital Episode Statistics on  1,088,782 arthroscopic partial meniscectomies (1997-2017); 699 965 of which were eligible for analysis. They sought to identify complications occurring in the 90 days after the index procedure.

Serious complications occurred in 0·327% of cases, including 546 pulmonary embolisms (0·078%) and 944 infections necessitating further surgery (0·135%).  

For every 1390 fewer knee arthroscopies done, one pulmonary embolism could be prevented. For every 749 fewer procedures done, one native knee joint infection could be prevented.

Risk factors for serious complications included increasing age (adjusted odds ratio [aOR] 1·247 per decade [95% CI 1·208–1·288), higher modified Charlson comorbidity index (aOR 1·860 per 10 units).

Lower risks were seen in females (aOR 0·640) and risk of mortality fell over time. Serious complications, like death, myocardial infarction, and stroke occurred less frequently in the study cohort than in the general population.

The risks associated with arthroscopic meniscectomy were low, occasionally serious and have not changed with time.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Intraarticular Trans-Capsaicin Effective in Knee OA

A novel study has shown that intraarticular therapy with high‐purity synthetic trans‐capsaicin (CNTX‐4975) for chronic knee osteoarthritis (KOA) was associated with significant relief of knee pain.

Smoking Not Protective Against Knee OA

Researchers found no protective effect of smoking against knee osteoarthritis (OA), according to a new longitudinal cohort study of 620 individuals with meniscal tears treated at five sites in Denmark. An inverse association between OA and smoking had been suggested by several previous studies and a recent meta-analysis.  

FDA Approves Romosuzumab (Evenity) for High Risk Osteoporosis

The US Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of osteoporotic fracture, including those with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies.

Guidelines for Osteoporosis Management in Postmenopausal Women

New guidelines on the  "Pharmacologic Management of Osteoporosis in Postmenopausal Women," were presented March 25 at ENDO 2019 - The Endocrine Society Annual Meeting and simultaneously published online in the Journal of Clinical Endocrinology & Metabolism. 

Risky Painkillers Commonly Prescribed for Osteoarthritis

Published guidelines warn that treating osteoarthritis (OA) with opioids and benzodiazepines can boost patients' risk of falling. Nevertheless, physicians in a large health system were prescribing those drugs for the condition nearly a third of the time, often in the vulnerable elderly, according to a study reported here.